AAV基因疗法新病例显示潜在肿瘤风险
STAT+: New tumor cases show common gene therapy tool can come with risk
研究人员和家庭面临AAV基因疗法的肿瘤风险与救命潜力之间的权衡,这将改变某些患者的治疗决策。
揭示了AAV基因疗法与肿瘤风险之间的关联,对患者选择治疗方案有重要影响。
![]()
By Jason Mast
Nov. 6, 2026
General Assignment Reporter
For two decades, researchers debated whether adeno-associated viruses, the small viruses used to deliver new genes into thousands of patients, could in certain cases drive tumors. That debate is over.
A series of cases this year has presented powerful evidence that adeno-associated viruses, or AAVs, can cause cancer, forcing researchers and families to weigh the newly confirmed risk against the technology’s lifesaving potential — and hopefully determine how to design better therapies in the future.
“It will change the calculus for some patients,” said Sam Mackenzie, a neurologist at University of Rochester, speaking specifically about spinal muscular atrophy patients.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com